Scarica l'app Stockscreener
1.60
2.44%
-0.04
Dopo l'orario di chiusura:
1.57
-0.03
-1.88%
Chemomab Therapeutics Ltd Adr Borsa (CMMB) Ultime notizie
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab reports progress in PSC treatment trial - Investing.com
Roth MKM Initiates Coverage of Chemomab Therapeutics LtdADR (CMMB) with Buy Recommendation - MSN
The Chemomab Therapeutics Ltd ADR (CMMB) had a good session last reading, didn’t it? - US Post News
Financial Health Check: Examining Chemomab Therapeutics Ltd ADR (CMMB)’s Key Ratios - The Dwinnex
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ratios Uncovered: Breaking Down Chemomab Therapeutics Ltd ADR (CMMB)’s Trailing Twelve Months Metrics - The Dwinnex
Is Chemomab Therapeutics Ltd ADR (CMMB) a good investment opportunity? - US Post News
CMMB stock touches 52-week high at $2.07 amid market fluctuations - Investing.com
Chemomab Therapeutics Ltd ADR (CMMB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Are Chemomab Therapeutics Ltd ADR (CMMB) shares a good deal now? - US Post News
CMMB stock touches 52-week high at $1.58 amid market fluctuations - Investing.com India
Chemomab Therapeutics Ltd ADR (CMMB) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Analysts see American Express Co. [AXP] gaining to $265. Time to buy? - The DBT News
Chemomab Therapeutics Ltd ADR [CMMB] moved down -16.20: Why It’s Important - The DBT News
Chemomab regains Nasdaq compliance with bid price rule - Investing.com
Public Service Enterprise Group Inc. [PEG] Revenue clocked in at $9.72 billion, up 21.41% YTD: What’s Next? - The DBT News
Cerevel Therapeutics Holdings Inc [CERE] Is Currently 2.37 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Ardelyx Inc [ARDX] moved down -2.31: Why It’s Important - The DBT News
CMMB’s 2023 Market Dance: Up 107.84% – Time to Invest? - The InvestChronicle
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga
Chemomab secures $10 million in PIPE financing - Investing.com India
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy? - Yahoo News Malaysia
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - MSN
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - Investing.com India
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update - Investing.com India
LGVN Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Why Copart, Inc. (CPRT) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Chemomab Stock: Leading Anti-CCL24 mAb For Fibrotic Diseases (NASDAQ:CMMB) - Seeking Alpha
Chemomab And AGC Biologics Partner To Manufacture CM-101 For Phase II/III - Contract Pharma
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal - Yahoo Finance
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):